(Q43921056)

English

HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity

scientific article published in January 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

author name string

Chiun Hsu

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Chin-Lun Huang

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Hey-Chi Hsu

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Shiou-Jeng Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

language of work or name

0 references

publication date

1 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

94

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

415-420

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Treatment of hepatocellular carcinoma: too many options?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

C-erbB-2 immunostaining: problems with interpretation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Heregulin regulation of Akt/protein kinase B in breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Prognostic histologic features of resected small hepatocellular carcinoma (HCC) in Taiwan. A comparison with resected large HCC

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Experts debate value of HER2 testing methods

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

2 references

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

https://api.crossref.org/works/10.1002%2FCNCR.10180

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10180

21 January 2018

Identifiers

10.1002/CNCR.10180

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43921056&oldid=2164762184"